Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2014

View Archived Issues

Nymox reports nerve sparing and sexual preservation data on NX-1207

Pfizer and Cellectis establish cancer immunotherapy collaboration

Kyowa Hakko Kirin to begin a phase I trial of KHK-6640 for Alzheimer's disease

Flexion reports pharmacokinetic results for FX-006 in knee osteoarthritis

First data presented for ZP-GG-72, a dual GLP-1/2 agonist

Biosimilar infliximab BOW-015 shows equivalence in phase III trial

ProMetic completes phase I trial of PBI-4050

Protalix BioTherapeutics initiates phase II study of PRX-112

Zalicus licenses sodium channel pain modulation program to AnaBios

MRC Technology sells melanocortin receptor program to Pfizer

Janssen enters into license agreement with Vertex for influenza A treatment

Ziarco secures grant from U.K.'s Technology Strategy Board to advance ZPL-389

Asmacure discloses topline results of phase I/IIa trial of ASM-024 dry powder inhaler

Global ALS/MND Day news: Compounds with surprising effects in experimental ALS

Novel agents for cancer disclosed by Agios Pharmaceuticals

Researchers at AbbVie disclose novel PDE10A inhibitors

Portuguese group divulges agents for tuberculosis

Novartis patents new monophosphate prodrugs for viral infections

Merck & Co. designs novel gamma-secretase inhibitors

AT-13148 well tolerated in ongoing first-in-human study

Novel Ga-68 PET bone-targeting agent tested in vivo, ex vivo and in metastatic bone cancer patients

Sumitomo Dainippon Pharma approved as new English trade name

FDA accepts Cubist's NDA for ceftolozane sulfate/tazobactam sodium

Intec Pharma reports animal safety data for the Accordion Pill for carbidopa/levodopa

Sorafenib approved in Japan for thyroid carcinoma

Shire rejects acquisition proposal from AbbVie

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...